Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Rahman MA, Amin AR, Wang X, Zuckerman JE, Choi CH, Zhou B, Wang D, Nannapaneni S, Koenig L, Chen Z, Chen ZG, Yen Y, Davis ME, Shin DM.

J Control Release. 2012 May 10;159(3):384-92. doi: 10.1016/j.jconrel.2012.01.045. Epub 2012 Feb 8.

2.

RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.

Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG, Shin DM.

Clin Cancer Res. 2013 Jul 1;19(13):3416-28. doi: 10.1158/1078-0432.CCR-13-0073. Epub 2013 May 29.

3.

Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.

Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H, Dai J, Guo Y.

Biomaterials. 2013 Dec;34(38):10084-98. doi: 10.1016/j.biomaterials.2013.08.088. Epub 2013 Sep 20.

PMID:
24060417
4.

Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.

Iwamoto K, Nakashiro K, Tanaka H, Tokuzen N, Hamakawa H.

Int J Oncol. 2015 May;46(5):1971-7. doi: 10.3892/ijo.2015.2912. Epub 2015 Mar 2.

PMID:
25738429
5.

Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer.

Chen WH, Lecaros RL, Tseng YC, Huang L, Hsu YC.

Cancer Lett. 2015 Apr 1;359(1):65-74. doi: 10.1016/j.canlet.2014.12.052. Epub 2015 Jan 14.

6.

RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.

Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.

Oncogene. 2004 Feb 26;23(8):1539-48.

PMID:
14661056
7.

Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo.

Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME.

Clin Cancer Res. 2007 Apr 1;13(7):2207-15.

8.

Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.

Zhang M, Wang J, Yao R, Wang L.

Int J Gynecol Cancer. 2013 May;23(4):659-66. doi: 10.1097/IGC.0b013e318287e2b3.

PMID:
23466567
9.

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A.

Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.

10.
11.

Targeting HOTAIR Induces Mitochondria Related Apoptosis and Inhibits Tumor Growth in Head and Neck Squamous Cell Carcinoma in vitro and in vivo.

Kong L, Zhou X, Wu Y, Wang Y, Chen L, Li P, Liu S, Sun S, Ren Y, Mei M, Wang X, Zhang L.

Curr Mol Med. 2015;15(10):952-60.

PMID:
26592246
12.

Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells.

Lo WL, Chien Y, Chiou GY, Tseng LM, Hsu HS, Chang YL, Lu KH, Chien CS, Wang ML, Chen YW, Huang PI, Hu FW, Yu CC, Chu PY, Chiou SH.

Biomaterials. 2012 May;33(14):3693-709. doi: 10.1016/j.biomaterials.2012.01.016. Epub 2012 Feb 21.

PMID:
22361100
13.

Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.

Kang W, Tong JH, Chan AW, Zhao J, Wang S, Dong Y, Sin FM, Yeung S, Cheng AS, Yu J, To K.

Oncol Rep. 2014 Jun;31(6):2579-86. doi: 10.3892/or.2014.3148. Epub 2014 Apr 23.

PMID:
24756820
14.

Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.

Shah KN, Wilson EA, Malla R, Elford HL, Faridi JS.

Mol Cancer Ther. 2015 Nov;14(11):2411-21. doi: 10.1158/1535-7163.MCT-14-0689. Epub 2015 Sep 2.

15.

Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.

Martens-de Kemp SR, Nagel R, Stigter-van Walsum M, van der Meulen IH, van Beusechem VW, Braakhuis BJ, Brakenhoff RH.

Clin Cancer Res. 2013 Apr 15;19(8):1994-2003. doi: 10.1158/1078-0432.CCR-12-2539. Epub 2013 Feb 26.

17.

Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.

Shen S, Mao CQ, Yang XZ, Du XJ, Liu Y, Zhu YH, Wang J.

Mol Pharm. 2014 Aug 4;11(8):2612-22. doi: 10.1021/mp400714z. Epub 2014 Feb 20.

PMID:
24521262
18.

[Effect of cinobufotalin on growth of xenograft of endometrial carcinoma cell line ishikawa in nude mouse and its impact on RRM2 expression].

Feng K, Zhou HJ, Hu YL.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Nov;30(11):1183-5. Chinese.

PMID:
21275172
19.

Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.

Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE.

Surgery. 2004 Aug;136(2):261-9.

PMID:
15300189
20.

siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide.

Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A.

J Invest Dermatol. 2011 Feb;131(2):453-60. doi: 10.1038/jid.2010.310. Epub 2010 Oct 14.

Supplemental Content

Support Center